Rationale and design of a multicenter, randomized phase II trial of durvalumab with or without multitarget tyrosine kinase inhibitor as maintenance treatment in extensive-stage small-cell lung cancer patients (DURABLE study).
Bo ZhangHua ZhongChunlei ShiZhiqiang GaoRunbo ZhongAiqin GuWeimin WangTianqing ChuLiwen XiongWei ZhangHuimin WangXueyan ZhangBao-Hui HanPublished in: The clinical respiratory journal (2023)
We conduct a phase II study to investigate the safety and efficacy of durvalumab combined with anlotinib as maintenance treatment in ES-SCLC patients.